Every 10-Q that PMV Pharmaceuticals, Inc (PMVP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PMVP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PMVP filings page.
PMV Pharmaceuticals, Inc. reported continued operating losses for the quarter and six months ended June 30, 2026 while advancing its lead oncology candidate, rezatapopt. Net loss was $18.1 million for the quarter and $36.1 million for the first half of 2026. Cash, cash equivalents, and marketable securities totaled $79.4 million at June 30, 2026, with management estimating this will fund planned operations only through the second quarter of 2027 and disclosing substantial doubt about its ability to continue as a going concern.
Research and development expenses were $30.0 million for the first half, primarily related to rezatapopt and the Phase 2 pivotal PYNNACLE trial. The FDA granted Orphan Drug Designation in March 2026 for rezatapopt in TP53 Y220C positive ovarian, fallopian tube, and primary peritoneal cancers, and enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis has been completed. The company plans to seek accelerated approval with an initial NDA submission targeted for the first quarter of 2027.
PMV Pharmaceuticals reported another quarter of operating losses as it advances its lead cancer drug rezatapopt. For the three months ended March 31, 2026, the company posted a net loss of $18.0 million, similar to the prior-year loss of $17.4 million, as it remains in clinical development with no product revenue.
Research and development expense fell to $15.3 million from $17.4 million, mainly from lower contract research costs on rezatapopt, while general and administrative expense declined to $3.7 million. Interest income decreased to $1.0 million from $1.9 million due to lower balances and rates.
Cash, cash equivalents, and marketable securities totaled $93.5 million, and management believes this will fund operations until the end of the second quarter of 2027. The company highlighted ongoing pivotal Phase 2 work in the PYNNACLE trial and noted that rezatapopt received Orphan Drug Designation in March 2026 for TP53 Y220C–positive ovarian, fallopian tube, and primary peritoneal cancer, with plans to file a New Drug Application in the first quarter of 2027.
PMV Pharmaceuticals (PMVP) filed its Q3 2025 10‑Q, reporting continued clinical investment and a wider loss as it advances rezatapopt. For the three months ended September 30, 2025, net loss was $21.1 million ($0.40 per share). Operating expenses were $22.5 million, driven by research and development of $18.2 million and general and administrative of $4.3 million. Interest income was $1.5 million.
For the nine months, net loss was $59.7 million, with $56.4 million used in operating cash flow. Cash, cash equivalents, and marketable securities totaled $129.3 million as of September 30, 2025. The company states it has adequate liquidity to operate for the next 12 months. Common shares outstanding were 52,993,238 at quarter‑end; 53,211,507 were outstanding as of November 12, 2025.
PMV reported interim Phase 2 data updates for the PYNNACLE trial of rezatapopt and plans to complete enrollment in the ovarian cohort by the first quarter of 2026, with an NDA submission targeted for the first quarter of 2027. The at‑the‑market program had $113.8 million of capacity remaining, with no sales during the quarter.